Sep 11, 2026 · 7 min
European stocks weigh drug risk as cities plan for growth
Novo Nordisk Drops, Puma Down, Trainline Rises
The episode connects immediate corporate pressures in European markets with the longer-term challenge of building cities that can absorb rapid urbanization.
- 1Novo Nordisk faces a downgrade and patent-cliff concerns that sharpen questions about its outlook.
- 2Puma’s leadership uncertainty contrasts with Trainline’s strong trading update and £100 million buyback.
- 3Smart-city planning combines artificial intelligence, long-term infrastructure decisions, and Dubai’s response to population growth.
Don't miss
Trainline’s strong trading update and £100 million buyback stand out as the clearest positive market signal in the report.
The brief
European markets set the opening stakes: Novo Nordisk faces a downgrade and patent-cliff concerns, while Puma contends with management uncertainty.
Trainline provides the counterpoint with a strong trading update and a £100 million buyback, signaling confidence amid a mixed stock-movers report.
The episode then widens from company-specific risk to urban systems, asking how artificial intelligence and long-term planning can make cities smarter.
Jacob Greaves hosts a discussion with Rohit Krishnan and Estefanía Tapias on AI, infrastructure, and Dubai’s response to rapid population growth.
The through-line is adaptation: companies must navigate changing commercial conditions, while cities must design systems for growth before pressure peaks.
What was said on this episode
12 statements · 3 positive · 9 negative
Generic competition will emerge for GLP-1s in some markets
“generic competition is going to start coming quite soon”
Listen at 1:05
GLP-1 generic competition will begin around the mid-2030s
“about the mid-2030s is going to start happening”
Listen at 1:08
Loss of exclusivity will challenge Novo Nordisk
“this loss of exclusivity on some of those drugs is going to be a huge challenge for Novo Nordisk”
Listen at 1:12
Novo Nordisk’s weight-loss pill missed expectations
“The weight loss pill did not manage to beat expectations.”
Listen at 1:43
Puma sales will remain weak through 2026
“the sales are still likely to continue being very weak throughout the rest of this year of 2026”
Listen at 2:35
Puma may recover starting in 2027
“things that can sort of get back on track starting in 2027”
Listen at 2:46
Lululemon recently cut its guidance
“Lululemon cutting its guidance recently”
Listen at 2:54
Nike and Adidas are struggling with investor sentiment
“Nike and Adidas are struggling to get back in investors' good graces”
Listen at 2:56
Extreme European heat reduced international rail demand
“the extreme heat that we've seen in Europe has hurt the demand in some parts of the international”
Listen at 3:34
Trainline’s UK business is in good shape
“the UK business is looking actually in pretty good shape”
Listen at 3:42
Trainline’s trading update reduced pressure on its shares
“this trading update has helped to relieve some of that pressure”
Listen at 4:14
Trainline shares are down about 10% year to date
“we're still down about 10% year to date for the company”
Listen at 4:18
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Bloomberg: Business News DailyListen to the full episode and explore every guest, topic, and moment on PodLume.